Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477672 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Phase 3 study of Parkinson's Disease Psychosis, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 298
- Enrollment target
- 20
- Study locations
NCT00477672 is a Phase 3 study of Parkinson's Disease Psychosis that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 298 participants, above the 217-participant average among 3 other Parkinson's Disease Psychosis trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00477672, a Phase 3 study of Parkinson's Disease Psychosis, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 298 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pimavanserin tartrate (ACP-103)
Study Locations (20)
Florida
- - Boca Raton
- - Gainesville
- - Jacksonville
- - Miami
- - Pompano Beach
- - Port Charlotte
- - Sarasota
- - St. Petersburg
- - Tampa
California
- - Berkeley
- - Carson
- - Fountain Valley
- - Irvine
- - Sunnyvale
Arizona
- - Gilbert
- - Phoenix
Connecticut
- - Danbury
- - Fairfield
Georgia
- - Augusta
Illinois
- - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477672
The ClinicalTrials.gov registry entry for NCT00477672 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 3 other Parkinson's Disease Psychosis trials with a reported enrollment target (37% higher). The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00477672 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00477672 about?
NCT00477672 is a clinical study titled "A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis". This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
What is the current status of trial NCT00477672?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 298 participants. The study started on 2007-06. Estimated completion is 2009-07.
What conditions does trial NCT00477672 study?
This clinical trial studies the following conditions: Parkinson's Disease Psychosis.
What interventions are being tested in trial NCT00477672?
The interventions under investigation include: Placebo (DRUG), Pimavanserin tartrate (ACP-103) (DRUG).
Who is sponsoring clinical trial NCT00477672?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00477672 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease Psychosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.